Employees: 18
Size Tevogen (TVGN) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $422M, the 2798th largest of 3,085 United States companies the cockpit tracks. Shares closed at $6.14 on 18 Nov 2026.
Performance Over six months the shares fell 37.8%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$250,228 | -$509,197 | -$403,581 | -$378,357 | $0 |
| EBITDA | -$22.3M | -$25.6M | -$53.2M | -$8.46M | -$953,080 |
| Net income | -$22.9M | -$26.3M | -$10.1M | -$60.5M | $4.41M |
| Free cash flow | -$9.94M | -$12.4M | -$12.0M | -$8.30M | -$215,400 |
| Capital expenditure | $64,439 | $64,439 | $0 | $133,000 | $0 |
| Total debt | $10.4M | $7.50M | $2.89M | $95.4M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TVGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.0% | -13.0% | 9th highest of 21 |
| 6-month return | -37.8% | -20.4% | 7th lowest of 21 |
| Distance from 52-week high | -75.3% | -47.7% | 2nd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tevogen TVGN | United States | $422M | -38% | n/a | n/a | n/a | n/a | n/a |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $421M | -31% | +1% | -39% | 7.1× | n/a | n/a |
| JW Pharmaceutical 001060.KS | South Korea | $423M | -26% | +9% | 13% | 0.7× | -15.4% | +7.2% |
| Beijing Foyou Pharma 601089.SS | China | $423M | -27% | +5% | 10% | 0.2× | n/a | n/a |
| Synmosa Biopharma 4114.TWO | Taiwan | $423M | -1% | +21% | 10% | 2.2× | 5.4% | +15.3% |
| Hyundai Bioscience 048410.KS | South Korea | $424M | -50% | +78% | -580% | 164.0× | n/a | n/a |
| Teyi Pharmaceutical 002728.SZ | China | $419M | -12% | -7% | 7% | 3.2× | 24.4% | +8.0% |
| Ovid Therapeutics OVID | United States | $427M | -5% | -78% | -4,700% | 208.3× | n/a | n/a |
| Zota Health Care ZOTA.NS | India | $427M | +9% | +69% | -16% | 6.2× | n/a | n/a |
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $427M | +4% | -4% | 3% | 1.2× | 10.6% | +1.4% |
| Zhuhai Rundu Pharmaceutical 002923.SZ | China | $430M | -30% | +14% | 5% | 2.2× | 1.4% | -1.3% |
| Phathom Pharmaceuticals PHAT | United States | $431M | -55% | +87% | -9% | 2.9× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $412M | +64% | +6,162% | -194% | 119.7× | n/a | n/a |
| Rezolute RZLT | United States | $411M | +32% | n/a | n/a | n/a | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $433M | -48% | +51% | 27% | 3.4× | -0.2% | +14.5% |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $433M | -47% | +35% | 4% | 1.1× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $433M | -42% | -14% | -12% | 2.9× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $410M | -49% | -88% | -676% | 4.7× | n/a | n/a |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $407M | -15% | -16% | 7% | 1.7× | -3.2% | +11.2% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $437M | -8% | -17% | -28% | 10.6× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $437M | -12% | -49% | 5% | 2.1× | -5.6% | -5.6% |